• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Dr Stephen Wiviott

Dr. Stephen D. Wiviott is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) in 1990 and Harvard Medical School (Honors) in 1996.  He served as a Medical House Officer and Chief Medical Resident at Brigham and Women’s Hospital.  Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women’s Hospital. After completion of his training he has joined the faculty of the Cardiovascular Division of Brigham and Women’s Hospital and serves as Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with the TIMI Study Group.

As an investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group he has played important roles in the planning, implementation and interpretation of several multicenter, national and international clinical trials.  He has played leadership roles in the JUMBO – TIMI 26 trial and the TRITON – TIMI 38 trial the major phase 2 and phase 3 trials of prasugrel a third generation thienopyridine.  He was the Principal Investigator of PRINCIPLE – TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI and of the TIMI 38 Coronary Stent Registry, an ongoing international registry of the long-term outcomes of patients receiving different types of intracoronary stents for acute coronary syndromes.  He was a lead physician for the LANCELOT program evaluating the novel antiplatelet agent atopaxar, a PAR-1 antagonist.

In addition, Dr Wiviott has played major roles in the design and implementation of several trials of metabolic therapies (lipid lowering, weight loss and anti-diabetic therapies) in patients with acute coronary syndromes or chronic atherosclerotic disease.  These trials include trials of intensive statin therapy PROVE IT – TIMI 22, A to Z TIMI 25 in ACS, and of the cholesteryl esterase transfer protein (CETP) inhibitor anacetrapib in the ongoing REVEAL – HPS 3 – TIMI 55.  He is world-wide co-prinicipal investigator for the DECLARE – TIMI 58 trial, the largest clinical outcomes study of an SGLT-2 inhibitor in patients with type 2 diabetes and CAMELLIA – TIMI 61, a cardiovascular outcomes study of the weight loss agent lorcaserin.

Dr. Wiviott serves as the physician chairman of the TIMI Clinical Events Committee, a leading event adjudication group in cardiovascular disease. In this role, he has served as chairman of major studies ranging from 100s to more than 10,000 endpoints evaluated – in CV disease, neurology, oncology, hepatology, and endocrinology – supporting major publications and registration of new medications by regulatory agencies world-wide.   As an expert in event adjudication, he has served as leader for major projects to define and evaluate cardiovascular events in clinical-trials in collaboration with academics, industry and US regulators.

Dr. Wiviott is an author of more than one hundred and fifty peer-reviewed publications in major medical and cardiovascular journals including the New England Journal of Medicine, JAMA, Lancet, Circulation, JACC and the European Heart Journal as well as multiple chapters in major cardiovascular textbooks including Braunwald’s Heart Disease. He was named in 2014 by Thompson Reuters one of “The World’s Most Influential Scientific Minds” in Medicine based on impact of his publications.   Dr. Wiviott has delivered local, national and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, metabolic agents, and anticoagulants.  Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, and metabolic therapies.

« Dr Dariush Mozaffarian
Professor Stefan Neubauer »

Cardiology, Diabetes & Nephrology at the Limits Canada
Wednesday, 3 & Thursday, 4 March 2021, Virtual Meeting

Cardiology, Diabetes & Nephrology at the Limits 2021
Monday, 12 & Tuesday, 13 April 2021, Virtual Meeting

The 18th Malvern Diabetic Foot Conference
Wednesday, 12 – Friday, 14 May 2021, Malvern, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 10 & Saturday, 11 September 2021, London, UK

Multiple Sclerosis at the Limits
Monday, 13 & Tuesday, 14 September 2021, London, UK

Hatter Horizon GP Meeting
Monday, 1 November 2021
London, UK

Cell Therapy at the Limits 2021
Monday, 8 & Tuesday, 9 November 2021, London, UK

Hatter Horizon Series
Monday, 22 November 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 10 - Saturday, 11 December 2021, São Paulo, Brazil

Policy links

  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2021 At the Limits Ltd.
This site uses cookies More info